Multi-disciplinary Consensus Statement Document. Vaccinal Prevention in Adults Patients with Diabetes Mellitus


Dos Santos G. et al. Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review. Hum Vaccin Immunother. 2018.

Amos AF. et al. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997.

Casqueiro J. et. al. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian Journal of Endocrinology and Metabolism / 2012 / Vol 16 / Supplement 1.

Goeijenbier M. et. al. Benefits of flu vaccination for persons with diabetes mellitus: A review. Vaccine 35 (2017) 5095–5101.

Papagianni M. et al. Herpes Zoster and Diabetes Mellitus: A Review. Diabetes Ther (2018) 9:545–550.

Shah BR. et al. Quantifying the Risk of Infectious Diseases for People With Diabetes. Diabetes Care 26:510–513, 2003.

Lau D. et al. Working-age adults with diabetes experience greater susceptibility to seasonal influenza: a population-based cohort study. Diabetologia (2014) 57:690–698.

Allard R. et al. Diabetes and the Severity of Pandemic Influenza A (H1N1) Infection. Diabetes Care 33:1491–1493, 2010.

Mertz D. et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ 2013;347:f5061.

Istituto Superiore di Sanità. Monitoraggio dell’andamento delle forme gravi e complicate di influenza confermata (2017-18).

Piano Nazionale Prevenzione Vaccinale (PNPV) 2017-19. 18-2-2017.

Ministero della Salute. Direzione Generale della Prevenzione Sanitaria. Prevenzione e controllo dell’influenza: raccomandazioni per la stagione 2018-2019. 30 maggio 2018.

AMD e SID: Standard Italiani per la Cura del Diabete Mellito 2018.

Kwong JC. et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med 378;4. January 2018.

MacIntyre CR. et al. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart 2016;102:1953–1956.

Colquhoun AJ. et al. Effectiveness of infuenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol. Infect. (1997), 119, 335±341.

Vamos EP. et al. Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes. CMAJ, October 4, 2016, 188(14).

Kuan Wang I. et al. Effectiveness of influenza vaccination in elderly diabetic patients: A retrospective cohort study. Vaccine 31 (2013) 718– 724.

Sheridan PA. et al. The antibody response to influenza vaccination is not impaired in type 2 diabetics. Vaccine. 2015 June 26; 33(29): 3306–3313.

Sistema Sorveglianza PASSI. Coperture vaccinali antinfluenzale malati cronici adulti (18-64 anni).

Jiménez-Garcia R. et al. Influenza vaccination in people with type 2 diabetes, coverage, predictors of uptake, and perceptions. Result of the MADIABETES cohort a 7 years follow up study. Vaccine 35 (2017) 101–108.

Verger P. et al. Characteristics of patients and physicians correlated with regular influenza vaccination in patients treated for type 2 diabetes: a follow-up study from 2008 to 2011 in southeastern France. Clin Microbiol Infect 2015; 21: 930.e1–930.e9.

2017 Censis report: la vaccinazione antinfluenzale nel nuovo assetto demografico.

Torres A. et al. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax 2015;0:1–6.

Suaya JA. et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine 36 (2018) 1477–1483.

Lopez-de-Andres A. et al. Hospitalisation with community acquired pneumonia among patients with type 2 diabetes: an observational population-based study in Spain from 2004 to 2013. BMJ Open 2017;7:e013097

Sheng Kuo C. et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly. Medicine (2016) 95:26

Beam TR. et al. Antibody response to polyvalent polysaccharide vaccine in diabetics. JAMA. 1980 Dec 12;244(23):2621-4.

Friedman EA. et al. Intact antibody response to pneumococcal capsular polysaccharide in uremia and diabetes. JAMA. 1980 Nov 21;244(20):2310-1.

Geerlings SE. et al, Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunology and Medical Microbiology 26 (1999) 259^265.


Clancy U. et al. Prevalence and predictors of influenza and pneumococcal vaccine uptake in patients with diabetes. Ir Med J. 2012 Oct; 105(9):298-300.

Alvarez CE. aet al. Survey of vaccination practices in patients with diabetes: A report examining patient and provider perceptions and barriers. Journal of Clinical & Translational Endocrinology 9 (2017) 15–17.

Kawai K. et al. Risk Factors for Herpes Zoster: a Systematic Review and Meta-analysis. Mayo Clin Proc. 2017. Dec 92(12):1806-1821.

Suaya JA. et al. Incidence of Herpes Zoster and Persistent Post-Zoster Pain in Adults With or Without Diabetes in the United States. Open Forum Infectious Diseases 2014 Aug 2; 1(2).

Weitzman D. et al. A population based study of the epidemiology of Herpes Zoster and its complications. Journal of Infection (2013) 67, 463e469.

Centers for Disease Control and prevention (CDC). Seasonal Influenza (Flu).